Frontlight ResearchEarly access
Taking peoplePhase 2
Clinical Trial on PREnatal Dexamethasone In Congenital adrenal hyperplasia Therapy - PREDICT -
Key facts
- Who runs it
- Philipps-Universitaet Marburg
- Where
- Germany2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 122 people, planned
- Started
- 5 Aug 2025
- Expected to end
- 1 Jan 2035
- Type of study
- Interventional
- Record updated
- 3 June 2026
Who can take part
- Age
- Up to 64 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Adult pregnant females with risk of classic CAH in their fetuses (genetic mutations in both parents)
- Written informed consent of the pregnant mother and the legal guardians of the unborn child
- GW <8+0 post menstruationem
Who cannot take part
- Subjects on regular daily inhaled, topical, nasal or oral steroids for any indication other than therapy of CAH in the fetus or in the CAH affected mother herself
- Participation in a clinical trial of an investigational or licensed drug or device within the 3 months prior to inclusion in this study
- Co-morbid condition requiring daily administration of a medication (or use of any medications/supplements) that interferes with the metabolism of glucocorticoids
- History of malignancy (other than basal cell carcinoma successfully treated)
- Clinical or biochemical evidence of hepatic or renal disease. Creatinine over twice the upper limit of normal (ULN) or elevated liver function tests (ALT or AST >2 times ULN])
- Body weight <50 kg or >95 kg before pregnancy
- Subjects unable to comply with the requirements of the protocol
- Pregnancy with twins or multiples
This trial is currently available in Germany.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To investigate if a reduced dexamethasone dose is effective and non-inferior to the currently experimentally used high (“standard”) dose regimen in preventing prenatal virilization in females with classic congenital adrenal hyperplasia (CAH) and to investigate the effect on maternal weight gain during gestation (GWG)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 3 June 2026